drugset / Trial / NCT04174612
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
RandomizedParallel-groupOpen-labelTreatment
Summary
Prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC
Timeline
- Start
- 2020-04-24
- Primary completion
- 2022-12
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 1500 mg | — |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | — |
| Background | Midostaurin | Small molecule | 50 mg | — |